Literature DB >> 32217130

A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.

Jian Zhang1, Chang Zou2, Chenzhi Zhou3, Yifeng Luo4, Qiong He5, Yu Sun6, Jianwen Zhou4, Zunfu Ke7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32217130     DOI： 10.1016/j.jtho.2020.03.009

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.

Authors:  Wanwan Cheng; Chunfa Qian; Haitao Zhang; Qi Meng; Jiani C Yin; Shencun Fang
Journal:  Anticancer Drugs       Date:  2022-08-09       Impact factor: 2.389

2.  A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung.

Authors:  Xiaojing Jia; Qianru He; Xiaodan Xing; Yanming Yang; Yan Ma
Journal:  Onco Targets Ther       Date:  2022-03-14       Impact factor: 4.147

3.  Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.

Authors:  Y Yao; Z Yu; Y Ma; Q Ou; X Wu; D Lu; X Li
Journal:  ESMO Open       Date:  2022-03-16

4.  Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.

Authors:  Huanling Xia; Binbin Liang; Guoxiang Liu; Yingxue Qi; Ningning Luo; Mengmeng Li
Journal:  Medicine (Baltimore)       Date:  2022-04-08       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.